CJC-1295: Research Applications
🔬 Adult Growth Hormone Deficiency (GHD) and Somatopause
CJC-1295 tem sido investigado(a) in GH-axis research (GHD, age-related somatopause). Phase I data (Teichman et al., 2006) in adultos saudaveis (n=64) reported GH and IGF-1 endpoints over 9–11 days after a single administration. [3]
🔬 Body Composition Research
GH and IGF-1 signaling regulate lipolysis and protein synthesis. Estudos pre-clinicos in rodent models demonstrate que sustained GHRH receptor ativacao aumenta massa corporal magra and reduz tecido adiposo — effects mediated via IGF-1 signaling in muscle and fat tissue. [5] CJC-1295 with DAC produz continuous IGF-1 elevation que may amplify these composicao corporal effects comparado(a) a pulsatile delivery approaches.
🔬 Metabolic Research — HIV-Associated Lipodystrophy
Phase II trials in adults with HIV-associated lipodystrophy (fat redistribuicao syndrome) were iniciou by ConjuChem antes do(a) company's closure. This population was selected porque HIV antiretroviral therapy is associated with peripheral lipoatrophy and central fat accumulation, with secondary GH axis supressao. CJC-1295 with DAC was hypothesized para restaurar GH/IGF-1 physiology and normalize fat distribuicao — a clinically meaningful endpoint in this population. [4] Development was discontinued sem publication of Phase II results.
🔬 Pediatric GHD (Preclinical Model)
Alba et al. (2006) studied GRF analogues in GH-deficient modelo de ratos, providing preclinical GH-axis data in a GHD model. CJC-1295 with DAC showed dose-dependente normalization of growth parameters in hypophysectomized rodents — the standard in vivo model for GHD. [7]
🔬 Pituitary Biology and GH Axis Research
CJC-1295 with DAC serves como um(a) pharmacological tool compound for studying tonic vs. pulsatile GH axis estimulacao. Because it provides continuous, week-long GHRHr ativacao, it enables researchers to decouple o efeitos of GH pulse frequency from GH pulse amplitude — questions relevant to GH-axis physiology. [2]
| Research Domain | Evidence Level | Achado Principal |
|---|---|---|
| GHD/Somatopause | Phase I clinical | GH ↑ 1.5–3× for 9–11 days after a single administration |
| Body composition | Preclinical | Lean mass ↑, massa gorda ↓ in rodent models |
| HIV lipodystrophy | Phase II iniciou | Development discontinued; results unpublished |
| Pediatric GHD | Preclinical | Growth normalization in hypophysectomized rats |
| Pituitary biology | Preclinical/in vitro | Tool compound for tonic vs. pulsatile GH research |
“(2005) — EndocrinologyPreclinical/early PKEstablished DAC albumin-binding kinetics; confirmou covalent albumin-Cys34 bond Alba et al.”
Referencias
- Jetté L, et al. (2005). Endocrinology, 146(7):3052–3058.
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of hormonio do crescimento (GH) persists during continuous estimulacao by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12):4792–4797.
- Teichman SL, et al. (2006). J Clin Endocrinol Metab, 91(3):799–805.
- Alba M, et al. (2006). Once-monthly administration of CJC-1295, a long-acting hormonio do crescimento-releasing hormone (GHRH) analog, normalizes growth no(a) GHRH-deficient dwarf rat. Am J Physiol Endocrinol Metab, 291(6):E1290–E1294.
- Walker RF. (2006). Clin Interv Aging, 1(4):307–308.
- Ben-Shlomo A, et al. (2020). Growth hormone-releasing hormone (GHRH) e seu(sua) analogues: from bench to bedside. Neuroendocrinology, 110(3–4):192–199.
- Gahete MD, et al. (2009). In vivo e em vitro evidence para o(a) importance of hormonio do crescimento-releasing hormone no(a) regulacao of GH secretion. Mol Cell Endocrinol, 309(1–2):40–47.
- FDA. (2024). Substancia Farmaceutica a Granels Under Evaluation for Use in Compounding Under Section 503A: Categoria 2. Docket FDA-2013-N-1525. Federal Register, Dec 2024.
- WADA. (2024). List of Prohibited Substances and Methods. S2: Hormonios Peptidicos, Fatores de Crescimento, Substancias Relacionadas e Mimeticos. World Anti-Doping Agency.
- Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocr Rev, 7(3):223–253.
Perguntas de Pesquisa Relacionadas
Related research
Deseja a revisao completa da pesquisa?
Explorar a biblioteca de pesquisa de peptídeos→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.